News & Updates

Use of the monoclonal antibody sotrovimab within 10 days of COVID-19 diagnosis appears to reduce the risk of hospitalization, mortality, and need for respiratory support in patients at high risk of progression to severe illness, according to large real-world data.

Increasing D-dimer is a useful predictor of negative clinical outcomes among individuals with invasive infections driven by Neisseria Meningitidis, suggests a study.

For individuals who completed treatment for pulmonary tuberculosis (TB), vaccination with H56:IC31 does not appear to reduce the risk of disease recurrence, according to a phase 2b trial.

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The introduction of pneumococcal conjugate vaccines (PCV) into Singapore's National Childhood Immunisation Schedule (NCIS) has reduced the incidence of invasive pneumococcal disease (IPD) in children by nearly a third, as reported in a study.

Awareness about human papillomavirus (HPV) infection in males and the benefits of vaccination on both genders is low among young adults, reveals a Singapore study.

In children and adolescents who have contracted COVID-19, gastrointestinal (GI) tract symptoms may remain for up to 2 years, as reported in a large retrospective study.

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.